Key result
Carriers of at least one T allele in the VKORC1 C1173T polymorphism had a significantly increased risk of severe bleeding when using phenprocoumon (OR 2.6) compared to CC genotype individuals.
Why the study?
Does the VKORC1 C1173T polymorphism increase bleeding risk in patients on vitamin K antagonist therapy?
Population
330 patients on vitamin K antagonist therapy, including 110 severe bleeders and 220 non-bleeders, >96%…
Comparison
VKORC1 C1173T polymorphism vs VKORC1 CC genotype
Design
Case-control
Authors
Loading...
Does not support routine VKORC1 testing for phenprocoumon; leaves open whether genotyping improves VKA safety in prospective trials.
Case-Control (n=330)
Yes
Does the VKORC1 C1173T polymorphism increase bleeding risk in patients on vitamin K antagonist therapy?
Odds Ratio: 2.6 (95% CI 1.2–5.7)
The VKORC1 C1173T polymorphism is associated with an increased risk of severe bleeding in patients treated with phenprocoumon, highlighting a potential role for genetic testing to guide vitamin K antagonist therapy.
Reitsma et al. (2005) conducted a case-control in Severe bleeding during vitamin K antagonist therapy (n=330). VKORC1 C1173T polymorphism (T allele carrier) vs. CC genotype was evaluated on Severe bleeding in phenprocoumon users (OR 2.6, 95% CI 1.2-5.7). Carriers of at least one T allele in the VKORC1 C1173T polymorphism had a significantly increased risk of severe bleeding when using phenprocoumon (OR 2.6) compared to CC genotype individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: